
NICE Recommends Ebglyss for Moderate to Severe Atopic Dermatitis Treatment in NHS England for Eligible Adolescents and Adults
Lebrikizumab has been approved for treating moderate-to-severe atopic dermatitis in adolescents (12 years and older) and adults who require systemic therapy. This treatment received approval from the European Commission and the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) in…












